To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Gremese, Elisa;Moroni, G;
2015-01-01

Abstract

To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.
2015
Adult
Antibodies
Monoclonal
Murine-Derived
Antirheumatic Agents
Dose-Response Relationship
Drug
Drug Monitoring
Drug Resistance
Female
Humans
Immunosuppression
Italy
Lupus Erythematosus
Systemic
Male
Middle Aged
Off-Label Use
Remission Induction
Rituximab
Severity of Illness Index
Treatment Outcome
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/85775
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 96
  • ???jsp.display-item.citation.isi??? 88
social impact